Get the Stockscreener App
9.02
7.00%
+0.59
After Hours:
8.90
-0.12
-1.33%
Candel Therapeutics Inc stock is currently priced at $9.02, with a 24-hour trading volume of 1.00M.
It has seen a +7.00% increased in the last 24 hours and a +436.90% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.22 pivot point. If it approaches the $9.56 resistance level, significant changes may occur.
Previous Close:
$8.43
Open:
$8.34
24h Volume:
1.00M
Market Cap:
$264.71M
Revenue:
$124.00K
Net Income/Loss:
$-37.94M
P/E Ratio:
-8.1261
EPS:
-1.11
Net Cash Flow:
$-34.70M
1W Performance:
+41.16%
1M Performance:
+436.90%
6M Performance:
+1,236%
1Y Performance:
+467.30%
1D Range:
$8.34
$9.39
52W Range:
$0.66
$11.40
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617 916 5445
Address
117 Kendrick Street, Suite 450, Needham
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
Candel Therapeutics Inc Stock (CADL) Latest News
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Zacks Investment Research
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
GlobeNewswire Inc.
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Zacks Investment Research
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Candel Therapeutics Inc Stock (CADL) Financials Data
Candel Therapeutics Inc (CADL) Revenue 2024
CADL reported a revenue (TTM) of $124.00 thousand for the quarter ending December 31, 2022, a 0.00% decline year-over-year.
Candel Therapeutics Inc (CADL) Net Income 2024
CADL net income (TTM) was -$37.94 million for the quarter ending December 31, 2023, a -101.87% decrease year-over-year.
Candel Therapeutics Inc (CADL) Cash Flow 2024
CADL recorded a free cash flow (TTM) of -$34.70 million for the quarter ending December 31, 2023, a -6.07% decrease year-over-year.
Candel Therapeutics Inc (CADL) Earnings per Share 2024
CADL earnings per share (TTM) was -$1.30 for the quarter ending December 31, 2023, a -100.00% decline year-over-year.
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
1.62%
0.15%
Cap:
|
Volume (24h):